Ovarian Carcinoma

Oncology
7
Pipeline Programs
7
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
6
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
2100%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
Sacituzumab govitecanPhase 2ADC
Sacituzumab govitecanPhase 2ADC1 trial
Active Trials
NCT06028932Active Not Recruiting20Est. Nov 2027
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD2281Phase 21 trial
Active Trials
NCT00679783Completed99Est. Jul 2022
Biotest Pharmaceuticals
Biotest PharmaceuticalsGermany - Dreieich
1 program
1
NanoPac® 100 mg/m2Phase 21 trial
Active Trials
NCT03029585TerminatedEst. Nov 2019
Karyopharm Therapeutics
1 program
1
SelinexorPhase 21 trial
Active Trials
NCT02025985CompletedEst. Mar 2017
Bayer
BayerLEVERKUSEN, Germany
1 program
1
TamoxifenPhase 21 trial
Active Trials
NCT02584465Completed68Est. Sep 2021
Transgene
TransgeneFrance - Illkirch-Graffenstaden
1 program
1
TG4050Phase 11 trial
Active Trials
NCT03839524CompletedEst. Oct 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Gilead SciencesSacituzumab govitecan
Biotest PharmaceuticalsNanoPac® 100 mg/m2
BayerTamoxifen
Karyopharm TherapeuticsSelinexor
AstraZenecaAZD2281
TransgeneTG4050

Clinical Trials (6)

Total enrollment: 187 patients across 6 trials

NCT06028932Gilead SciencesSacituzumab govitecan

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Start: Jan 2024Est. completion: Nov 202720 patients
Phase 2Active Not Recruiting
NCT03029585Biotest PharmaceuticalsNanoPac® 100 mg/m2

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

Start: Apr 2017Est. completion: Nov 2019
Phase 2Terminated
NCT02584465BayerTamoxifen

REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

Start: Aug 2015Est. completion: Sep 202168 patients
Phase 2Completed
NCT02025985Karyopharm TherapeuticsSelinexor

Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies

Start: Apr 2014Est. completion: Mar 2017
Phase 2Completed
NCT00679783AstraZenecaAZD2281

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

Start: Jul 2008Est. completion: Jul 202299 patients
Phase 2Completed
NCT03839524TransgeneTG4050

A Trial Evaluating TG4050 in Ovarian Carcinoma.

Start: Dec 2019Est. completion: Oct 2024
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)